FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an anti-programmed cell death-1 (hereinafter – PD-1) antibody or its antigen-binding fragment, which specifically bind with PD-1, to a nucleic acid molecule encoding it, as well as to a composition containing the above-mentioned antibody or its fragment and immune-conjugate. A vector and a cell containing the above-mentioned nucleic acid molecule are also disclosed. The invention also relates to a method for producing the above-mentioned anti-PD-1 antibody or its antigen-binding fragment, as well as to a method for detecting PD-1 protein in a patient’s sample using the above-mentioned antibody or its fragment.
EFFECT: invention allows for effective treatment of cancer.
24 cl, 25 dwg, 6 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
